[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_9538",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_9538"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB01041"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma mm 1 1 thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl 1 2 thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma mm see clinical studies 14 1 thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence see clinical studies 14 2"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB01041",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-12T16:29:21.636+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "ZXlOjoIzDLCrD/wPGV2Lh7qzKEoRLXEbQrwurEoEBhECBhJMkAm2vrN49qOmZjdtHVS2mSQfCDSneszlcEet2Uldp4E4gysU6jQ4ELJsSITMun7VUqvLWk9g2oMGdTLGkWjTbzfnVdKepN/TlPYx5xm0HYZ5CS6p8jhA10PA1UY="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#pubinfo"
} ]